MyChesCo on MSN1d
Savara Completes BLA Submission for MOLBREEVI to Treat aPAP
LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) has announced the completion of its Biologics License Application (BLA) submission ...
Hosted on MSN1mon
Savara Inc. Publishes Promising Long-Term Outcomes for aPAP Treatment
Molgramostim works by stimulating alveolar macrophages that are otherwise ... This uncontrollable buildup causes impaired gas exchange, resulting in severe symptoms and potential long-term ...
dvm36012d
The build-up of pulmonary edema
The abnormal accumulation of extravascular fluid, pulmonary edema settles in the lung interstitium and alveoli. There, it ...
Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, ...
European Medical Journal4d
Long-Term Lung Damage After Severe COVID-19: New Findings
New research reveals that severe COVID-19 pneumonia can cause lasting lung damage, primarily due to impaired pulmonary ...
BBC2y
Alcohol and tobacco (CCEA)
Causes emphysema (alveolar damage reducing the surface area of gas exchange). Causes lung cancer (abnormal cell division). Nicotine Addictive and affects heart rate.